Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance

OBJECTIVE: The purpose of this study is to develop an anti-PDL1-based interferon (IFN) fusion protein to overcome the chronic hepatitis B virus (HBV)-induced immune tolerance, and combine this immunotherapy with a HBV vaccine to achieve the functional cure of chronic hepatitis B (CHB) infection. DES...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Chao-Yang, Sun, Shiyu, Liang, Yong, Xu, Hairong, Zhang, Chao, Zhang, Min, Wang, Fu-Sheng, Fu, Yang-Xin, Peng, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359590/
https://www.ncbi.nlm.nih.gov/pubmed/36316098
http://dx.doi.org/10.1136/gutjnl-2022-327059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359590/
https://www.ncbi.nlm.nih.gov/pubmed/36316098
http://dx.doi.org/10.1136/gutjnl-2022-327059

Ejemplares similares